Insights
Insights
Obtaining a NICE recommendation for your medical device: a view from the external assessors
Written by Mark Pennington, Consultant Health Economist
A National Institute for Health and Care Excellence ...
10 steps for a successful global economic model
Written by Beth Hancock, Senior Consultant Health Economist
Pharmaceutical companies often develop global ...
Conceptual modelling and NICE requirements: a significant change or hill of beans?
Written by Alec Miners, Head of Health Economics
The National Institute for Health and Care Excellence’s ...
British Heart Week 2022
As we approach the end of British Heart Week, we reflect on some of the key stats around heart conditions in the ...
Patient Participation Groups: A voice for patients for 50 years
Written by Dom Partridge, Medical Writer
6th to 13th June 2022 is Patient Participation Group (PPG) Awareness ...
The Innovative Medicines Fund is now available to fast-track non-cancer medicines recommended with managed access
The Innovative Medicines Fund (IMF) launched this month (June 2022) to support faster access to non-cancer drugs. This process involves NHS England and the National Institute for Health and Care Excellence (NICE) working in partnership with pharmaceutical companies to respond to the long-standing challenge of evaluating medicines and addressing the uncertainty around their effectiveness.
NICE tests a new approach for evaluating and reimbursing antimicrobials
Written by Chris Hellmund, Senior Medical Writer
Antimicrobial resistance is a major threat to global health that ...
A quick look at network meta-analyses for National Numeracy Day!
Written by Abby Paine, Statistician
It’s National Numeracy Day, which is run by National Numeracy, a charity that ...
Limiting conference abstract searching for systematic reviews
Written by Isobel Munro, Associate Systematic Review Analyst
The purpose of conducting a systematic literature ...
Moving from academia to consultancy, is it for you?
Written by Alec Miners, Head of Health Economics
Contemplating ‘change’ of any kind can be daunting. Choosing a ...
ILAP breakdown for UK HTAs and market access
Written by Luke Parkes, Assistant Project Manager
ILAP remit
It has been just over a year since the ...
Evidence hierarchy in GVDs: the use of non-randomised evidence following NICE’s recent methods update
Written by Pip White, Senior Medical Writer
The global value dossier (GVD) is a vital resource to ensure ...
No results found.